Fasiglifam 25 mg BID vs 50 mg QD

PHASE2TerminatedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

October 31, 2013

Primary Completion Date

January 31, 2014

Study Completion Date

January 31, 2014

Conditions
Type 2 Diabetes Mellitus
Interventions
DRUG

Fasiglifam

Fasiglifam tablets

DRUG

Placebo to fasiglifam

Fasiglifam placebo-matching tablets

Trial Locations (88)

Unknown

Goodyear

Long Beach

Los Angeles

North Hollywood

Norwalk

Tustin

Boynton Beach

Coral Gables

Miami

Orlando

Pembroke Pines

Decatur

Chicago

Avon

Franklin

Greenfield

Muncie

Council Bluffs

Topeka

Lexington

Metairie

Flint

Albuquerque

Charlotte

Greensboro

Mooresville

Morganton

Salisbury

Maumee

Norman

Corvallis

Portland

Harleysville

Levittown

Uniontown

Greer

Carrollton

Dallas

Edinburg

Houstan

Houston

New Braunfels

San Antonio

Spring

Salt Lake City

Burke

Manassas

Byala

Pleven

Plovdiv

Rousse

Sevlievo

Sofia

Varna

Lodz

Oświęcim

Poznan

Rzeszów

Sobótka

Torun

Zgierz

Baia Mare

Bucharest

Cluj-Napoca

Iași

Oradea

Ploieşti

Bardejov

Bratislava

Dolný Kubín

Komárno

Levice

Lučenec

Nitra

Pezinok

Sabinov

Stropkov

Svidník

Štúrovo

Kaohsiung City

Taichung

Tainan City

Taipei

Kharkiv

Kyiv

Simferopol

Ternopil

Vinnytsia

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Takeda

INDUSTRY

NCT01982253 - Fasiglifam 25 mg BID vs 50 mg QD | Biotech Hunter | Biotech Hunter